Minoxidil: New Areas of Opportunity!
DOI:
https://doi.org/10.14738/bjhr.1304.12120Keywords:
Minoxidil, High blood pressure, Alopecia, Vitiligo, Yellow nail syndrome, Skin, HairAbstract
Introduction: Minoxidil is a compound chemically synthesized in the laboratory, it underwent clinical trials in hypertensive patients in 1961. Objective: To carry out art history based on an exhaustive search of the national and international medical literature on its therapeutic use of minoxidil in humans. Discussion: the topical use of routine minoxidil for the treatment of multiple hair disorders. 2% and 5% minoxidil continue to be the approved treatments, with the most efficient being 5%, with an expected phase of loss, even under treatment. Another use that has been reported for minoxidil is that used together with phototherapy, it is the most common treatment for vitiligo; A novel bioengineering approach to improve local delivery in the skin. The hydrogels are highly mechanically robust micro-needle patches with heights of 600 or 800 μm with sufficient mechanical strength to penetrate human skin. Minoxidil has been used in yellow nail syndrome, a rare disorder characterized by a triad of thickened yellow nails, primary lymphedema, and chronic respiratory manifestations. It has been determined as a treatment as an antihypertensive drug and has been studied since 2008, stating that minoxidil should be used together with β-blockers and diuretics. Conclusions: Minoxidil has demonstrated beneficial effects in androgenic alopecia, scarring and alopecia areata; however, it has been shown that there are other areas of therapeutic opportunities in other diseases, due to their already known pharmacological actions, evoking the option of new research protocols
References
Stewart, K. Minoxidil. Enciclopedia Británica, 19 de marzo de 2025. https://www.britannica.com/topic/minoxidil.
Zins GR. The history of the development of minoxidil. Clin Dermatol. 1988; 6(4):132-47.
The Pharmaceutical Journal , PJ, julio de 2011;(): DOI:10.1211/PJ.2021.1.69888.
Gottlieb T.B., Katz F.H., Chidsey C.A 3rd. Combined therapy with vasodilator drugs and betaadrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972 Mar;45(3):571-82.
Pluss R.G., Orcutt J., Chidsey C.A. Tissue distribution and hypotensive effects of minoxidil in normotensive rats. J Lab Clin Med. 1972; 79(4):639-47.
Gottlieb T.B., Thomas R.C., Chidsey C.A. Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther. 1972; 13(3):436-41.
Bursztyn M, Ben-Dov IZ. Contemporary Use of an Old Drug: Minoxidil for Resistant Hypertension. Hypertension. 2025 Apr;82(4):543-548. doi: 10.1161/HYPERTENSIONAHA.124.23976.
Pettinger W.A., Mitchell H.C. Minoxidil: An alternative to nephrectomy for refractory hypertension. N Engl J Med 1973 ; 289 : 167 – 171.
Jaafari M.R. Enhancing targeted delivery and efficacy of PEGylated liposomal doxorubicin with liposomal minoxidil: comprehensive in silico, in vitro, and in vivo tumor model studies. Drug Deliv. 2025; 32(1):2536802.
Tan J.J.Y., Thuya W.L., Zhu H., et al. Comparative analysis of 3D and 2D cell-culturing methods in hair follicle spheroid morphogenesis and drug responsiveness. Biomater Adv. 2025 Dec;177:214423.
Levine J., Sharma D., Morsia S., Ungar B. Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil. J Dermatolog Treat. 2025; 36(1):2528704. doi: 10.1080/09546634.2025.2528704.
Bi L., Kan H., Wang J., et al. Whether the transient hair shedding phase exists after minoxidil treatment and does it predict treatment efficacy? A retrospective study in androgenetic alopecia patients. J Dermatolog Treat. 2025; 36(1):2480739.
Sharma D., Morsia S., Ungar B. Low-dose oral minoxidil in a case of short anagen syndrome. J Dermatolog Treat. 2025; 36(1):2460580.
Hu X., Guo L., Ding Y., et al. Self-assembling peptide inspired by insulin and type 1 insulin-like growth factor for the treatment of androgenetic alopecia. Bioact Mater. 2025; 53:819-830.
Tran NT, Truong MD, Yun HW, Min BH. A novel cell-free regenerative therapy for hair loss: human fetal cartilage progenitor cell secretome. Biomaterials. 2026 Feb;325:123627. doi: 10.1016/j.biomaterials.2025.123627.
Alosaimi A, Algarni A, Alharbi A, Alotaibi A, Alomairi A, Alsurayhi M, Alharbi W. Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis. J Dermatolog Treat. 2025 Dec;36(1):2447355. doi: 10.1080/09546634.2024.2447355. Scholar Publishing
Suchonwanit P, Rojhirunsakool S, Khunkhet S. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. Lasers Med Sci. 2019 Dec;34(9):1857-1864.
Zhao Z, Wang Y, Xing H, Wang Y, Lv K, Pan X, Chen T, Hu Y, Li G, Ma D. Optimizing efficacy: Hyaluronic acid liposomes encapsulating minoxidil for enhanced transdermal delivery and treatment of androgenetic alopecia. Colloids Surf B Biointerfaces. 2025 Nov;255:114956. doi: 10.1016/j.colsurfb.2025.114956.
Khazaeli P, Karamouzian M, Rohani S, Sadeghirad B, Ghalekhani N. Effects of minoxidil gel on burn wound healing in rats. Iran J Pharm Res. 2014 Winter;13(1):243-51
Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol. 2020 Jan;82(1):252-253.
Abid A, Fazal F, Mumtaz H, Raja HAA, Malik BH. Comparison of the efficacy of platelet-rich plasma with topical minoxidil in treating patients with androgenetic alopecia: a systematic review of clinical trials. Skin Health Dis. 2025 Jul 23;5(5):311-318. doi: 10.1093/skinhd/vzaf040.
Rivetti N. Xerostomia as a Rare Adverse Effect of Low-Dose Oral Minoxidil: A Case Report With Recurrence After Rechallenge. Clin Case Rep. 2025 Sep 24;13(10):e70993. doi: 10.1002/ccr3.70993.
Werachattawatchai P, Khunkhet S, Harnchoowong S, Lertphanichkul C. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study. Int J Womens Dermatol. 2025 Sep 19;11(3):e227. doi: 10.1097/JW9.0000000000000227.
Francis N, Craiglow BG. Treatment of Short Anagen Syndrome With Low-Dose Oral Minoxidil. Pediatr Dermatol. 2025 Sep 26. doi: 10.1111/pde.70049. Epub ahead of print.
Liu C, Liu X, Shi T, Wang Y, Sui C, Zhang W, Wang B. Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Front Pharmacol. 2025 Jun 3;16:1556705. doi: 10.3389/fphar.2025.1556705
Ohyama M, Irisawa R, Uchiyama M, Mori M, Aoki K, Ueda Y, Fujita T. Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial. J Dermatol. 2025 Sep;52(9):1351-1359. doi: 10.1111/1346-8138.17844.
Kearney CA, Maguire CA, Oza VS, Oh CS, Occidental MA, Shapiro J, Orlow SJ, Glasser CL, Lacouture ME, Lakdawala NR, Lo Sicco KI. Alopecia in Children with Cancer: A Review from Pathophysiology to Management. Am J Clin Dermatol. 2025 Sep;26(5):747-759. doi: 10.1007/s40257-025-00960-w.
Landells I, Chow E, Gupta AK, Jasso Olivares JC, Thuraisingam T, Ahluwalia R, Tan JKL, Pratt M, Yadav G, Chivers Q, Vezina N, Laforest T, Raad E, Owen J, Dayeh NR. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. J Cutan Med Surg. 2025 Sep 23:12034754251368849. doi: 10.1177/12034754251368849.
Chen CJ, Fang CL, Weng KC, Chen MH, Wang M, Chen EL, Fang JY. Systematic parametric analysis of drug properties and injection conditions in nebulized jet stream-mediated skin delivery. Int J Pharm. 2025 Sep 15;682:125974. doi: 10.1016/j.ijpharm.2025.125974.
Nilforoushzadeh MA, Heidari A, Heidari N, Nobari NN. Regenerative Potential of Adipose Tissue-Derived Exosomes in Treating Hair Shaft Abnormalities: A Case Report. Case Rep Dermatol Med. 2025 Sep 11;2025:8838962. doi: 10.1155/crdm/8838962. Scholar Publishing
Zaminski D, Garshick M, Shapiro J, Sicco KL, Mazori DR. Response to "The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System". J Cosmet Dermatol. 2025 Sep;24(9):e70423. doi: 10.1111/jocd.70423.
Ahmed Jan N, Masood S. Vitiligo. [Actualizado el 7 de agosto de 2023]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; enero de 2026-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK559149/[
Wang X, Ju X, He C. Nitric Oxide Donor and Minoxidil Co-Loaded Microneedles Improving Hair Loss Treatment. Macromol Biosci. 2025 Aug 6:e00225. doi: 10.1002/mabi.202500225.
Mawu FO, Sondakh ORL, Kairupan TS, Christopher PM. Comparative efficacy and safety of lowlevel laser therapy and topical Minoxidil combination vs. topical Minoxidil monotherapy in androgenetic alopecia management: a systematic review and meta-analysis of randomized controlled trials. Lasers Med Sci. 2025 Aug 19;40(1):338. doi: 10.1007/s10103-025-04593-7.
Chen X, Xie Y, Wei A. Combined Corticosteroid and Minoxidil Therapy for Early Recovery in Radiation-Induced Alopecia: A Case Report. Clin Cosmet Investig Dermatol. 2025 Jun 17;18:1495-1499. doi: 10.2147/CCID.S520575
Bajoria S, Srinivas CR, Satish N, Sukhija R, Jain K, Manocha G, Besra L. Phototherapy with Topical Minoxidil in Vitiligo: A Randomized Control Trial. Indian Dermatol Online J. 2025 Aug 14. doi: 10.4103/idoj.idoj_1242_24.
Desai D, Nohria A, Brinks A, Needle C, Sikora M, Mandal S, Shapiro J, Caplan AS, Garshick M, Lo Sicco KI. Impact of underlying medical conditions and medications on edema development in alopecia patients treated with low-dose oral minoxidil: A retrospective study. JAAD Int. 2025 Jun 16;22:32-34. doi: 10.1016/j.jdin.2025.05.010.
Harbi E, Yildiz O, Aschner M. Potential Risks of Minoxidil in Pheochromocytoma and Paraganglioma: A Commentary on Safety Concerns and Mechanisms. Mol Neurobiol. 2025 Jul;62(7):9170-9174. doi: 10.1007/s12035-025-04842-4.
Moreno-Arrones OM, Hermosa-Gelbard A, Saceda-Corralo D, Jimenez-Cauhe J, Ortega-Quijano D, Pirmez R, Vañó-Galván S. [Translated article] High-dose Oral Minoxidil for the Treatment of Androgenetic Alopecia. Actas Dermosifiliogr. 2025 Jul-Aug;116(7):T769-T772. English, Spanish. doi: 10.1016/j.ad.2025.05.018.
Kakurai M, Moriyama Y. Minoxidil Overdose: A Case Report and Review of the Literature. Cureus. 2025 Jun 21;17(6):e86505. doi: 10.7759/cureus.86505.
Sah AK, Sahoo J, Mishra C, Panda BB. Transient vision loss and achromatopsia associated with use of minoxidil. BMJ Case Rep. 2025 May 21;18(5):e265291. doi: 10.1136/bcr-2025-265291.
Nakarmi P, Hermiz J, Vempati R, Chandna S, Bhagat U, Loree S, Toquica Gahona C. Cardiac Tamponade due to Minoxidil use: A Case Report and Review of the Literature. Eur J Case Rep Intern Med. 2025 May 6;12(6):005379. doi: 10.12890/2025_005379.
Alkhwildi H, Alsaffar S, Bethlehem C. A Rare Case of Peripheral Edema Induced by Topical Minoxidil: A Case Report. Curr Drug Saf. 2025 May 6. doi: 10.2174/0115748863383206250417083121.
Junge A, Radonjic-Hoesli S, Bossart S, Simon D, De Viragh P, Hunger RE, Heidemeyer K, Seyed Jafari SM. Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. Acta Derm Venereol. 2025 Apr 27;105:adv42401. doi: 10.2340/actadv.v105.42401.
García MA, Aceituno A, Díaz NB, Tapia EM, Contreras D, López-Lagos C, Sánchez V, González PM. Exploring Experimental and Statistical Approaches to Control Oversensitivity of In Vitro Scholar Publishing Permeability to Excipient Effects. Pharmaceutics. 2025 Aug 26;17(9):1110. doi: 10.3390/pharmaceutics17091110.
Li P, Zhu L, Guo X, Jin W, Hu J, Chen Y, Lu J. A commentary on "The efficacy of diltiazem, glyceryl trinitrate, nifedipine, minoxidil, and lidocaine for the medical management of anal fissure: a systematic review and network meta-analysis of randomized controlled trials". Int J Surg. 2025 Jun 1;111(6):4132-4133. doi: 10.1097/JS9.0000000000002410.
Li Y, Bi D, Hu Z, Yang Y, Liu Y, Leung WK. Hydrogel-Forming Microneedles with Applications in Oral Diseases Management. Materials (Basel). 2023 Jul 3;16(13):4805. doi: 10.3390/ma16134805.
Wang LL, Tuohy S, Kim E, Nace A, Xu KL, Yang R, Zheng Y, Cotsarelis G. Controlled Release of Minoxidil through Hydrogel Cross-Linking to Treat Androgenetic Alopecia. ACS Biomater Sci Eng. 2025 Jul 14;11(7):4062-4067. doi: 10.1021/acsbiomaterials.5c00292.
Desai K, Lev-Tov H, Morrison BW. Oral Minoxidil Use in Yellow Nail Syndrome: Report of 2 Cases. Skin Appendage Disord. 2025 May 28:1-4. doi: 10.1159/000546583.
Geier B, Roy B, Reiter LT. Small molecule ion channel agonist/antagonist screen reveals seizure suppression via glial Irk2 activation in a Drosophila model of Dup15q syndrome. Neurobiol Dis. 2025 May;208:106882. doi: 10.1016/j.nbd.2025.106882.
Needle CD, Brinks AL, Kearney CA, Shapiro J, Lo Sicco KI. Key considerations of injectable minoxidil for alopecia. Arch Dermatol Res. 2025 Mar 17;317(1):572. doi: 10.1007/s00403-025-04068-3.
Dong W, Gutierrez L, Cadd R, Sung CT. Injectable Minoxidil for Hair Loss Disorders: A Systematic Review. J Drugs Dermatol. 2024 Dec 1;23(12):1084-1088. doi: 10.36849/jdd.8301.
Kim J, Kim D. Dimethylsiloxane polymers for the effective transdermal delivery of Minoxidil in hair loss treatment. Biomed Eng Lett. 2025 Jan 29;15(2):437-442. doi: 10.1007/s13534-025-00460-0.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Luis Octavio Victoria García, Morelos Adolfo García Sánchez, Rafael Martínez Sanciprián, Miranda Llama Luna, Mariana Carolina Zúñiga García, Luis Alberto González Valdez, Marco Antonio Hernández Hernández, Oscar Gregorio Ramírez Gamboa, Karla Lizeth Martínez González, Melba Michelle Romero Ovando, Zarah Georgina Pérez Diosdado
This work is licensed under a Creative Commons Attribution 4.0 International License.
